PepTalk 2017
PepTalk 2017

Pipeline Five Header

Cambridge Healthtech Institute’s Third Annual
Characterization of Biotherapeutics
Improving Prediction, Screening and Characterization of New Biologics
January 9-10, 2017 | Hilton San Diego Bayfront | San Diego, CA


New biotherapeutics formats are flooding the discovery and development pipelines and with this comes an increasing need for better and faster characterization tools and strategies, and improved biomolecular and biophysical assays for the new biotherapeutics. The Third Annual Characterization of Biotherapeutics conference presents new tools, strategies and case studies on analytical development and characterization of mAbs, ADCs, bispecifics, and other novel protein formats.

We invite you to present a poster and attend to join colleagues in this discussion of the key challenges and solutions improving prediction, screening and characterization of new biologics.

Preliminary Agenda


SCREENING, CHARACTERIZATION AND DEVELOPMENT
OF NEW BIOTHERAPEUTICS

Understanding Chemical Liabilities in Antibody Lead Selection

Shrikant Deshpande, Ph.D., Senior Director, Protein Chemistry, Biologics Discovery California, Bristol-Myers Squibb Co.

Characterization of Protein Products

Sambit Kar, Ph.D., Principal Scientist; Head, Biophysics Center of Excellence, Molecular & Analytical Development, Bristol-Myers Squibb Co.

Biophysical Characterization to Enable the Formulation Development of Multi-Dose Aggregation-Prone Peptide Conjugates

Jingtao Zhang, Ph.D., Principal Scientist, Pharmaceutical Sciences, Merck Research Laboratories


BIOSIMILARITY AND COMPARABILITY

Biosimilars – Analysis and Challenges

Gerard Powell, Ph.D., Senior Principal Specialist, Product Characterisation, Allergan Biologics Ltd., Liverpool, United Kingdom

Analytical Comparability and Characterization of a Non-covalent Heterodimer Biotherapeutic

Justin Prien, Ph.D., Associate Director, Analytical Development, Shire

Bleeding-Edge Characterization of Biosimilars

Edward R. Zartler, Ph.D., Senior Group Leader, Biophysics, Analytical R&D, Pfizer, Inc.


APPLICATION OF MASS SPECTROSCOPY
AND OTHER ANALYTICAL TECHNIQUES

Use of Time-Resolved Fluorescence Spectroscopy for Higher-Order Structure Characterization

Michael Ignatov, Ph.D., Senior Scientist, Allergan

FTIR Spectroscopy as a Multi-Parameter Analytical Tool for Stability Studies and Batch Consistency Testing of Therapeutic Proteins

Allison Derenne, Ph.D., CEO, SFMB Lab, Spectralys Biotech (ULB)

Use of Fast LC/MS Techniques to Identify, Characterize and Evaluate Therapeutic Antibodies

Amy Hilderbrand, Ph.D., Technical Development Scientist, Protein Analytical Chemistry, Genentech




For questions about the meeting, please contact:

Nandini Kashyap
Conference Director
Cambridge Healthtech Institute
Phone: 781-972-5406
Email: nkashyap@healthtech.com

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com